Table 2.

Growth outcomes and changes from baseline after 1 year of GH treatment using easypod for patients (A) overall and (B) who were GH naïve at start of easypod use.

Growth outcome	GHD (n = 886)	SGA (n = 206)	Turner syndrome (n = 82)	Othera/missing (n = 16)	Overall (n = 1190)
(A) Easypod adherence data analysis set
Baseline height SDS (s.d.)	−2.15 (0.98)	−2.45 (0.95)	−2.47 (0.96)	−2.41 (0.80)	−2.23 (0.98)
Change in height SDS at 1 year	0.47 (0.27; 0.69)	0.50 (0.29; 0.68)	0.41 (0.19; 0.65)	0.44 (0.15; 0.51)	0.47 (0.27; 0.68)
Baseline height velocity (cm/year)	4.00 (3.20; 5.00)	4.84 (3.92; 5.60)	4.08 (3.21; 5.55)	4.10 (3.60; 4.68)	4.00 (3.30; 5.10)
1-year height velocity (cm/year)	8.2 (6.9; 9.5)	8.3 (7.1; 9.3)	7.2 (5.6; 8.7)	8.0 (6.2; 8.8)	8.2 (6.9; 9.4)
1-year height velocity SDS	2.20 (0.62; 3.83)	2.09 (0.73; 3.3)	1.38 (−0.10; 2.19)	1.63 (0.80; 3.13)	2.11 (0.60; 3.62)
Growth outcome	Idiopathic isolated GHD (n = 166)	Organic GHD (congenital) (n = 23)	Organic GHD (tumour) (n = 27)	Non-GHDb (n = 390)	Overall (n = 606)
(B) Easypod adherence data analysis set – GH-naïve
Baseline height SDS (s.d.)	−2.27 (0.95)	−3.15 (1.15)	−1.53 (1.22)	−2.25 (0.88)	−2.26 (0.95)
Change in height SDS at 1 year	0.55 (0.35; 0.73)	0.72 (0.35; 1.03)	0.37 (0.15; 0.74)	0.47 (0.27; 0.69)	0.50 (0.28; 0.72)
Baseline height velocity (cm/year)	4.00 (3.50; 5.00)	4.33 (3.27; 7.00)	2.90 (1.70; 6.00)	4.00 (3.30; 5.08)	4.00 (3.30; 5.08)
1-year height velocity (cm/year)	8.4 (7.2; 9.7)	8.7 (7.3; 10.5)	8.20 (6.4; 9.3)	8.2 (6.9; 9.5)	8.3 (7.1; 9.6)
1-year height velocity SDS	2.54 (1.39; 3.65)	2.63 (0.67; 4.44)	2.35 (0.83; 4.18)	2.04 (0.59; 3.62)	2.15 (0.83; 3.69)

Values are presented as mean (s.d.) or median (Q1; Q3) unless stated otherwise.

^aOther indications include chronic renal failure/chronic kidney disease, short stature/slow growth and other; ^bnon-GHD includes patients with missing GHD origin.

GH, growth hormone; GHD, growth hormone deficiency; s.d., standard deviation; SDS, standard deviation score; SGA, small for gestational age.